The Department of Veterans Affairs (VA) National Acquisition Center is issuing a presolicitation notice for a Request for Proposal (RFP) #36E79725R0006 to procure Verapamil Hydrochloride (HCL) Tablets. This procurement aims to provide an uninterrupted supply of the drug for various federal entities, including the VA, Department of Defense (DoD), and Bureau of Prisons. The contract will have a duration of one year, with the potential for four additional one-year options. The total estimated annual requirements for the tablets are specified, with different dosages and quantities listed. Interested vendors must submit their proposals by December 4, 2024, and need to check the SAM.gov website for any updates regarding the solicitation. The procurement emphasizes the need for a unique National Drug Code (NDC) number and the drug's name must match the label. The main contact for this procurement is Contract Specialist Deborah Fassl. This notice reflects the VA's commitment to maintaining consistent pharmaceutical supplies for veterans and other federal healthcare entities.
The document outlines a solicitation from the Department of Veterans Affairs (VA) for pharmaceutical products, specifically for Verapamil HCL Tablets. The purpose is to establish a contract for the supply of these drugs through the VA and Department of Defense (DoD) Pharmaceutical Prime Vendor (PPV) Programs. The solicitation details include a request for pricing for the base year and four options, emphasizing a mandatory unique National Drug Code (NDC) for each product offered.
It specifies the requirement for manufacturers to maintain compliance with current Good Manufacturing Practices (cGMP) and their obligations regarding recalls and backorders. Contractors must submit quarterly sales reports, including a 0.5% Cost Recovery Fee. The document also outlines FDA regulations for drug registration, barcoding requirements, and drug supply chain security measures.
The contract's implementation and ordering periods are defined, indicating timelines for award notification and order placement. The document insists on proper bid submissions, clarifying that proposals failing to meet submission criteria or pricing conditions may be rejected. Overall, this solicitation aims to ensure the efficient and compliant procurement of pharmaceuticals for VA healthcare needs.
The document pertains to an amendment to a solicitation issued by the Department of Veterans Affairs, specifically for the procurement of Verapamil HCL Tablets (Solicitation Number 36E79725R0006). The main purpose of this amendment is to extend the due date and time for the receipt of offers from December 17, 2024, to December 24, 2024, at 2:30 PM CST. The amendment specifies that all other terms and conditions of the original solicitation remain unchanged. Instructions for acknowledgment of the amendment and its implications for offer submission are included, emphasizing the necessity for timely acknowledgment to avoid rejection of offers. The amendment is officially issued by the contracting officer, Nicholas I. McGregor, representing the OPAL / National Acquisition Center in Hines, Illinois. This document reflects standard procedures in federal contracting for extending deadlines while ensuring clarity and compliance among prospective bidders.